Search Results

DISAPEAR Registry Evaluates Abbott's Absorb BVS in Asian Cohort With CLTI

November 6, 2019—One-year results from the DISAPEAR registry evaluating the Absorb bioresorbable vascular scaffold (BVS; Abbott) were presented by Steven Kum, MD, in a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.

Midterm Results Published From Pilot Study of LimFlow's pDVA System

August 1, 2017—LimFlow SA announced that midterm outcomes from the pilot study of the LimFlow percutaneous deep vein arterialization (pDVA) system for the treatment of no-option critical limb ischemia (CLI) were published online by Steven Kum, MD, et al in the Journal of Endovascular Therapy (JEVT).

Treatment of Chronic Limb-Threatening Ischemia With Abbott's Absorb BVS Evaluated at 2 Years

November 7, 2020—A multicenter pooled analysis investigated the midterm outcomes of an infrapopliteal drug-eluting bioresorbable vascular scaffold (BVS) in the treatment of chronic limb-threatening ischemia (CLTI).

LimFlow System for Percutaneous Treatment of End-Stage CLI Receives CE Mark

November 15, 2016—LimFlow SA announced today it has received CE Mark approval for its fully percutaneous LimFlow System designed for venous arterialization of the lower limbs in end-stage patients at risk for limb amputation for critical limb ischemia (CLI).

FastWave Raises Funds to Accelerate Development of IVL Systems to Treat Cardiovascular Calcium

December 16, 2024—FastWave Medical, a clinical-stage medical device company, announced the close of a $19 million funding round earlier this year, increasing the total capital invested into the company to over $40 million.

Pedra Technology Secures Funding for Perfusion Monitoring Technology

September 22, 2020—Pedra Technology, a Singapore-based developer of deep tissue perfusion monitors, announced the completion of $4.7 million Series A financing.

Interim Results Presented for QT Vascular's Chocolate Touch

October 6, 2015—QT Vascular Ltd. announced the release of the interim results from ENDURE, the first study of the company’s Chocolate Touch peripheral drug-coated balloon to treat patients with above-the-knee peripheral artery disease.